Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
1.
JPGN Rep ; 3(2): e178, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-37168907

RESUMEN

Esophageal squamous papillomas (ESP) are rare benign tumors of the esophagus, which occur mostly in the adult population. Few cases have been reported in children and due to the low incidence, the pathogenesis of ESP is not entirely understood and the management is not standardized. It is thought that mucosal irritation from underlying inflammation, perhaps from GERD, trauma or human papilloma viruses can play a role in the formation of ESP. This report describes 4 cases of pediatric ESP from a single center and discusses the management of these lesions, including the use of antacids and the human papilloma viruses vaccine as treatment modalities. Given the limited data on ESP in the pediatric population, this report aims to describe the management of this condition in 1 center.

3.
Laryngoscope ; 129(5): 1159-1163, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30325515

RESUMEN

OBJECTIVE: To clarify the time course of recovery in patients with iatrogenic vocal fold paralysis. STUDY DESIGN: Retrospective chart review. METHODS: Medical records for all patients with iatrogenic vocal fold paralysis over a 10-year period were reviewed to obtain demographic and clinical information, including onset of disease and recovery of vocal function. Stroboscopic exams of patients who recovered voice were reviewed blindly to assess return of vocal fold motion. RESULTS: One hundred and two patients of 114 (89%) recovered vocal function. Time to recovery could be assessed in 39 patients who did not undergo injection augmentation. The mean time to recovery was 181.8 ± 109.3 days (left: 166.4 ± 106.7 days; right: 221.8 ± 115.6 days; P value = 0.095). Patients were analyzed according to anatomical site of surgery (skull base, carotid endarterectomy, thoracic, neck and intubation); there was no significant difference in time to recovery (P value = 0.60). Twelve of the 39 patients had recovery of vocal fold motion. The mean time to vocal recovery did not differ between patients with return of motion versus no return of motion (140.6 ± 118.0 days vs. 200.1 ± 102.2 days; P value = 0.147). CONCLUSION: Age, gender, laterality, and anatomical site of injury do not influence recovery rate in iatrogenic vocal fold paralysis. The probability of recovery decreases over time but more slowly in comparison with idiopathic vocal fold paralysis, reflecting the greater heterogeneity of injury type in the iatrogenic population. Commonly available aggregate recovery rates overstate the potential for recovery. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:1159-1163, 2019.


Asunto(s)
Parálisis de los Pliegues Vocales/etiología , Femenino , Humanos , Enfermedad Iatrogénica , Masculino , Persona de Mediana Edad , Recuperación de la Función , Estudios Retrospectivos , Factores de Tiempo , Pliegues Vocales/fisiología , Voz/fisiología
4.
Ear Nose Throat J ; 97(8): E39-E42, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30138525

RESUMEN

We conducted a retrospective chart review of 27 patients-7 men and 20 women, aged 47 to 94 years (mean: 71.3)-with symptomatic epiphora secondary to dacryostenosis who had undergone thulium: YAG (Tm:YAG) laser dacryocystorhinostomy (DCR). Among them, dacryostenosis had been documented in 35 eyes by dacryocystography. The Tm:YAG procedure involved the administration of local anesthesia, after which a 600-µm laser fiber was inserted into the lacrimal canaliculi and then into the nasolacrimal duct. Under endoscopic visualization, the DCR was performed anterior and inferior to the middle turbinate, which created an opening. Silicone stents were then inserted and tied intranasally. In the immediate postoperative period, all 27 patients noted initial improvement. During a follow-up of 22 days to 25 months (mean: 11.3 mo), 24 of the 27 patients (89%) remained symptom-free, while the remaining 3 patients (11%) experienced a treatment failure and required revision surgery. To the best of our knowledge, only two articles on thulium laser therapy for DCR have been previously published, both approximately 25 years ago; both involved the use of a thulium along with holmium and chromium in cadavers. As far as we know, our case series is the largest in the English-language literature that has documented the use of the thulium in laser therapy for DCR, and it is the only in vivo study. We found that DCR with the Tm:YAG laser was an effective and affordable option for patients with symptomatic epiphora secondary to lacrimal obstruction.


Asunto(s)
Dacriocistorrinostomía , Obstrucción del Conducto Lagrimal/terapia , Láseres de Estado Sólido/uso terapéutico , Tulio/uso terapéutico , Anciano , Anciano de 80 o más Años , Dacriocistorrinostomía/instrumentación , Dacriocistorrinostomía/métodos , Humanos , Masculino , Persona de Mediana Edad , Stents , Resultado del Tratamiento
5.
Laryngoscope ; 128(1): 177-183, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28543038

RESUMEN

OBJECTIVE: Our ability to speak is complex, and the role of the central nervous system in controlling speech production is often overlooked in the field of otolaryngology. In this brief review, we present an integrated overview of speech production with a focus on the role of central nervous system. The role of central control of voice production is then further discussed in relation to the potential pathophysiology of spasmodic dysphonia (SD). DATA SOURCES: Peer-review articles on central laryngeal control and SD were identified from PUBMED search. Selected articles were augmented with designated relevant publications. REVIEW METHODS: Publications that discussed central and peripheral nervous system control of voice production and the central pathophysiology of laryngeal dystonia were chosen. RESULTS: Our ability to speak is regulated by specialized complex mechanisms coordinated by high-level cortical signaling, brainstem reflexes, peripheral nerves, muscles, and mucosal actions. Recent studies suggest that SD results from a primary central disturbance associated with dysfunction at our highest levels of central voice control. The efficacy of botulinum toxin in treating SD may not be limited solely to its local effect on laryngeal muscles and also may modulate the disorder at the level of the central nervous system. CONCLUSION: Future therapeutic options that target the central nervous system may help modulate the underlying disorder in SD and allow clinicians to better understand the principal pathophysiology. LEVEL OF EVIDENCE: NA.Laryngoscope, 128:177-183, 2018.


Asunto(s)
Sistema Nervioso Central/fisiopatología , Disfonía/fisiopatología , Espasmo/fisiopatología , Trastornos de la Voz/fisiopatología , Humanos
6.
Laryngoscope ; 128(1): 148-152, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28736846

RESUMEN

OBJECTIVES/HYPOTHESIS: To clarify the time course of recovery in patients with idiopathic vocal fold paralysis. STUDY DESIGN: Retrospective chart review. METHODS: Medical records for all patients with idiopathic vocal fold paralysis over a 10-year period were reviewed to obtain demographic and clinical information, including onset of disease and recovery of vocal function. Stroboscopic exams of patients who recovered voice were reviewed blindly to assess return of vocal fold motion. RESULTS: Thirty-eight of 55 patients (69%) recovered vocal function. Time course of recovery could be assessed in 34 patients who did not undergo injection augmentation. The mean time to recovery was 152.8 ± 109.3 days (left, 179.8 ± 111.3 days; right, 105.3 ± 93.7 days; P = .088). Two-thirds of patients recovered within 6 months. Probability of recovery declined over time. Five of 22 patients who recovered voice had return of vocal fold motion; 17 did not. The mean time to recovery did not differ between these groups (return of motion, 127.4 ± 132.3 days; no return of motion, 160.1 ± 105.1 days; P = .290). CONCLUSIONS: Sixty-nine percent of patients with idiopathic vocal fold paralysis recovered vocal function, two-thirds doing so within 6 months of onset. Age, gender, laterality, use of injection augmentation did not influence recovery rate. Declining probability of recovery over time leads us to consider framework surgery after 6 months in patients with idiopathic paralysis. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:148-152, 2018.


Asunto(s)
Parálisis de los Pliegues Vocales/fisiopatología , Parálisis de los Pliegues Vocales/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recuperación de la Función , Estudios Retrospectivos , Estroboscopía , Factores de Tiempo
7.
Ann Otol Rhinol Laryngol ; 126(4): 340-343, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28103701

RESUMEN

OBJECTIVE: Metformin is an oral anti-hyperglycemic agent used to treat type 2 diabetes mellitus (DM). In vitro and animal models have shown that metformin can prevent the progression of oral lesions to carcinoma; however, there is conflicting data in the clinical literature regarding risk reduction for malignancy in head and neck cancer (HNC). STUDY DESIGN: Case series. METHODS: We present 3 cases in which adjuvant metformin therapy was used to treat recurrent and multifocal dysplastic lesions in previously treated nondiabetic HNC patients. RESULTS: Patients included 1 with a history of oral cavity squamous cell carcinoma (SCC) and 2 with a history of laryngeal SCC. Follow-up time ranged between 3 and 33 months. All 3 patients showed complete or partial regression of the remaining mucosal lesions and did not require any additional surgeries. CONCLUSION: We present 3 cases of nondiabetic HNC patients with field cancerization who showed a good response to adjuvant therapy with metformin. The nondiabetic population is not affected by confounding factors such as increased risk of malignancy and decreased overall survival that is itself associated with abnormal glucose metabolism and is therefore an excellent cohort in which to study the use of adjuvant metformin therapy in HNC patients.


Asunto(s)
Carcinoma de Células Escamosas/terapia , Neoplasias de Cabeza y Cuello/terapia , Hipoglucemiantes/uso terapéutico , Neoplasias Laríngeas/terapia , Leucoplasia/tratamiento farmacológico , Metformina/uso terapéutico , Neoplasias de la Boca/terapia , Recurrencia Local de Neoplasia/tratamiento farmacológico , Neoplasias de la Lengua/terapia , Anciano , Progresión de la Enfermedad , Femenino , Glotis , Humanos , Masculino , Membrana Mucosa , Carcinoma de Células Escamosas de Cabeza y Cuello
8.
Otolaryngol Head Neck Surg ; 155(3): 443-53, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27143710

RESUMEN

OBJECTIVE: Early differentiation of patients with unilateral vocal fold paralysis (VFP) who recover from those who do not and consequently require permanent medialization laryngoplasty (ML) remains a challenge. The goal of this study is to identify factors that predict the need for ML. STUDY DESIGN: Case series with chart review. SETTING: Academic center. SUBJECTS AND METHODS: A total of 507 records of patients with VFP were analyzed, of which 252 met criteria and were stratified according to whether or not they obtained ML. Demographic information and clinical features were analyzed to determine predictors of ML. A nomogram was generated according to the significance and utility of these parameters. RESULTS: Of 252 patients, 86 underwent ML, and 166 did not. No differences in age or sex were observed between the ML and non-ML patients (P = .27 and P = .35, respectively). The most common cause of VFP was iatrogenic injury (62.79%, ML; 49.40%, non-ML). ML correlated with VFP secondary to neoplastic disease (odds ratio [OR], 2.14; 95% confidence interval [95% CI], 1.01-4.53) and iatrogenic injury (OR 1.73; 95% CI 1.01-2.94). ML had an inverse correlation with idiopathic VFP (OR, 0.40; 95% CI, 0.20-0.79). Patients in the ML group were more likely to have left-sided VFP, to have a history of aspiration, and to present ≥90 days from onset and less likely to have had temporary injection augmentation. CONCLUSION: Clinical features may be used to predict the likelihood of a patient obtaining ML. Nomograms may be useful to counsel patients who would benefit from early definitive surgery.


Asunto(s)
Laringoplastia/métodos , Selección de Paciente , Parálisis de los Pliegues Vocales/cirugía , Comorbilidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nomogramas , Estudios Retrospectivos , Resultado del Tratamiento , Parálisis de los Pliegues Vocales/etiología
9.
Otolaryngol Head Neck Surg ; 155(3): 458-61, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27143711

RESUMEN

Chemodenervation with botulinum toxin (BoNT) has been effective and well tolerated for all types of dystonia for >30 years. We reviewed outcomes of our patients treated with BoNT serotype A (BoNT-A) for spasmodic dysphonia (SD) who became secondarily nonresponsive. We found that 8 of 1400 patients became nonresponsive to BoNT-A (0.57%), which is lower than the secondary nonresponse rate in other dystonias. After a cessation period, 4 of our patients resumed BoNT-A injections, and recurrence of immunoresistance was not seen in any of them. When compared with patients with other dystonias, patients with SD receive extremely low doses of BoNT. Small antigen challenge may explain the lower rate of immunoresistance and long-lasting efficacy after BoNT-A is restarted among secondary nonresponsive patients with SD.


Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Disfonía/tratamiento farmacológico , Fármacos Neuromusculares/uso terapéutico , Toxinas Botulínicas Tipo A/administración & dosificación , Femenino , Humanos , Masculino , Fármacos Neuromusculares/administración & dosificación , Resultado del Tratamiento
10.
Laryngoscope ; 126(3): 678-81, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26308153

RESUMEN

OBJECTIVES/HYPOTHESIS: Although onabotulinum neurotoxin A (BoNTA) has been used for over three decades for the treatment of adductor spasmodic dysphonia, no study has been performed to look at the trend of BoNTA dosages across time. The goal of this study is to evaluate the dosage trends to determine if the dosage necessary for voice improvement in patients increases over time. STUDY DESIGN: Charts were reviewed for patients with 15 years or more of experience. METHODS: Linear regression analysis was performed to determine correlation coefficients and trends. RESULTS: Fifty-five patients receiving BoNTA injections by the senior author (a.b.) for over 15 years were evaluated. Thirty-nine patients (82% female) met inclusion criteria. Patients received injections over an average of 18.6 years ± 1.36 years, with the longest follow-up of 21.5 years. Of 39 patients, 16 (41%) had a negative correlation coefficient (Pearson's r) suggesting a decrease over time, whereas 23 (59%) had a positive correlation coefficient suggesting an increase over time. The mean correlation coefficient was 0.139 ± 0.534 and P < 0.05 in 19 patients and P > 0.05 in 20 patients. R(2) for all patients were less than 0.75. CONCLUSIONS: Onabotulinum neurotoxin A injection dosage trends vary depending on the individual over time. Overall, the dose range appears to be stable in the majority of patients, suggesting that tolerance does not play a significant part in dose variation over time. LEVEL OF EVIDENCE: 4. Laryngoscope, 126:678-681, 2016.


Asunto(s)
Toxinas Botulínicas Tipo A/administración & dosificación , Disfonía/tratamiento farmacológico , Fármacos Neuromusculares/administración & dosificación , Calidad de la Voz/efectos de los fármacos , Adulto , Estudios de Cohortes , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Disfonía/diagnóstico , Femenino , Estudios de Seguimiento , Humanos , Inyecciones Intralesiones , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Medición de Riesgo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
12.
Toxins (Basel) ; 7(8): 2791-800, 2015 Jul 24.
Artículo en Inglés | MEDLINE | ID: mdl-26213970

RESUMEN

This article reviews the diagnoses and treatment of temporomandibular disorders (TMD) and outlines of the role of botulinum toxin (BoNT) in the treatment of myofacial TMD. This manuscript includes a brief history of the use of BoNT in the treatment of pain, the mechanism of action of BoNT, and the techniques for injections, adverse effects and contraindications when using BoNT to treat mayofacial pain caused by TMD.


Asunto(s)
Analgésicos/uso terapéutico , Toxinas Botulínicas/uso terapéutico , Dolor Facial/tratamiento farmacológico , Trastornos de la Articulación Temporomandibular/tratamiento farmacológico , Analgésicos/efectos adversos , Toxinas Botulínicas/efectos adversos , Contraindicaciones , Dolor Facial/diagnóstico , Humanos , Inyecciones , Trastornos de la Articulación Temporomandibular/diagnóstico
13.
Otolaryngol Clin North Am ; 48(4): 533-45, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26111895

RESUMEN

Laryngeal barriers to tumor spread are a product of laryngeal development, anatomic barriers, and enzymatic activity. Supraglottic and glottic/subglottic development is distinct and partially explains the metastatic behavior of laryngeal carcinoma. Dense connective tissues and elastic fibers provide anatomic barriers within the larynx. Laryngeal cartilage contains dense cartilage, enzyme inhibitors, and an intact perichondrium making it relatively resistant to tumor invasion; however, focal areas of vulnerability are created by ossified cartilage and natural interruptions in the perichondrium. Local inflammation and the enzymatic interplay between tumor and host are important factors in the spread of laryngeal tumor.


Asunto(s)
Glotis/anatomía & histología , Cartílagos Laríngeos/patología , Neoplasias Laríngeas/patología , Laringe/anatomía & histología , Humanos , Laringectomía
14.
Otolaryngol Head Neck Surg ; 151(6): 923-9, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25193517

RESUMEN

OBJECTIVES: The inconsistent measures used to report outcomes after mastoidectomy to treat cholesteatoma make it impossible for clinicians to compare results and apply them appropriately to patient care. We sought to identify and assess the type and relative frequency of the reported measures. DATA SOURCES: PubMed, EMBASE, the Web of Science. REVIEW METHODS: We searched 3 independent databases for articles that reported outcomes of middle ear cholesteatoma treated with mastoidectomy. Articles were assessed for eligibility using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol and data were extracted by 2 independent investigators. Observational studies and randomized controlled trials from the past 30 years were included. Articles with less than 50 subjects and nonsurgical studies were excluded. The measures used by each study were recorded, and the relative frequency of each measure was calculated. RESULTS: Forty-three of 380 articles met criteria. Time to follow up was inconsistent. Most articles reported on preoperative qualitative parameters (77%); however, few reported on the severity of disease (19%) or formally staged the disease (12%). Not all studies reported on the presence of recurrent or residual disease (88%) or the postoperative audiogram results (70%). Only 12% presented results as a Kaplan-Meier disease-free curve. Most studies reported on complications (70%). CONCLUSION: Reported measures were inconsistent among the studies, which makes comparisons between studies unreliable. Standardization will optimize future reporting and will allow for the establishment of best practices.


Asunto(s)
Colesteatoma del Oído Medio/diagnóstico , Colesteatoma del Oído Medio/cirugía , Apófisis Mastoides/cirugía , Procedimientos Quirúrgicos Otológicos/métodos , Femenino , Estudios de Seguimiento , Humanos , Masculino , Procedimientos Quirúrgicos Otológicos/efectos adversos , Complicaciones Posoperatorias/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Medición de Riesgo , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
15.
J Emerg Med ; 46(5): 650-4, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24508112

RESUMEN

BACKGROUND: Soccer continues to gain popularity among youth athletes, and increased numbers of children playing soccer can be expected to result in increased injuries. OBJECTIVE: We reviewed children with soccer injuries severe enough to require trauma activation at our Level I trauma center to determine injury patterns and outcome. Our goal is to raise awareness of the potential for injury in youth soccer. METHODS: A retrospective review was performed using the trauma registry and electronic medical records at a Level I trauma center to identify children (< 18 years old) treated for soccer injury from 1999-2009. Data reviewed include age, gender, mechanism, injury, procedures, and outcome. RESULTS: Eighty-one children treated for soccer injury were identified; 38 (47%) were male. Of these, 20 had injury severe enough to require trauma team activation and 61 had minor injury. Mean age was 14 years old (range 5-17 years, SD 2.3). Lower extremity was the most common site of injury (57%), followed by upper extremity (17%), head (16%), and torso (10%). Mechanisms were: kicked or kneed in 27 patients (33%), collision with another player in 25 (31%), fall in 18 (22%), struck by ball in 10 (12%), and unknown in 1 (1%). Procedures included reduction of fractures, splenectomy, abdominal abscess drainage, and surgical feeding access. Long hospitalizations were recorded in some cases. There were no deaths. CONCLUSION: Although less common, injury requiring prolonged hospital admission and invasive operative procedures exist in the expanding world of youth soccer. With increasing participation in the sport, we anticipate greater numbers of these child athletes presenting with serious injury.


Asunto(s)
Hospitalización , Fútbol/lesiones , Centros Traumatológicos/estadística & datos numéricos , Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Estudios Retrospectivos , Estados Unidos/epidemiología
16.
Otolaryngol Head Neck Surg ; 150(5): 824-6, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24486780

RESUMEN

Recovery from unilateral vocal-fold paralysis is lengthy, unpredictable, and often incomplete, highlighting the need for better treatments of the injured recurrent laryngeal nerve. To be able to monitor recovery of vocal-fold motion in studies with rats, we developed a procedure for quantitative video laryngoscopy. An asymmetry index was defined as a continuous and robust measure of unequal vocal-fold motion and calculated from spectral-density plots of vocal-fold displacements. In a cohort of 8 animals, unilateral vocal-fold paralysis was observed within seconds after clamping of the right recurrent laryngeal nerve and was accompanied by a markedly negative asymmetry index. Over the next month, the asymmetry index gradually returned to zero, concomitant with a visible recovery of vocal-fold motion. Our results suggest that quantitative video laryngoscopy is a sensitive and discriminating method for monitoring recovery from recurrent laryngeal nerve injury and set the stage for testing novel surgical and pharmacological treatments of unilateral vocal-fold paralysis.


Asunto(s)
Laringoscopía/métodos , Traumatismos del Nervio Laríngeo Recurrente/fisiopatología , Grabación en Video , Animales , Masculino , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Recuperación de la Función
18.
J Cell Biol ; 166(4): 591-600, 2004 Aug 16.
Artículo en Inglés | MEDLINE | ID: mdl-15302855

RESUMEN

Collagen XIX is an extremely rare extracellular matrix component that localizes to basement membrane zones and is transiently expressed by differentiating muscle cells. Characterization of mice harboring null and structural mutations of the collagen XIX (Col19a1) gene has revealed the critical contribution of this matrix protein to muscle physiology and differentiation. The phenotype includes smooth muscle motor dysfunction and hypertensive sphincter resulting from impaired swallowing-induced, nitric oxide-dependent relaxation of the sphincteric muscle. Muscle dysfunction was correlated with a disorganized matrix and a normal complement of enteric neurons and interstitial cells of Cajal. Mice without collagen XIX exhibit an additional defect, namely impaired smooth-to-skeletal muscle cell conversion in the abdominal segment of the esophagus. This developmental abnormality was accounted for by failed activation of myogenic regulatory factors that normally drive esophageal muscle transdifferentiation. Therefore, these findings identify collagen XIX as the first structural determinant of sphincteric muscle function, and as the first extrinsic factor of skeletal myogenesis in the murine esophagus.


Asunto(s)
Membrana Basal/metabolismo , Colágeno/metabolismo , Colágeno/fisiología , Esófago/fisiología , Músculos/metabolismo , Animales , Diferenciación Celular , Cuerpos Enrollados/metabolismo , Colágeno/genética , Unión Esofagogástrica/metabolismo , Matriz Extracelular/metabolismo , Colágenos Asociados a Fibrillas , Ratones , Músculos/patología , Mutación , Neuronas/metabolismo , Óxido Nítrico/metabolismo , Fenotipo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA